Stanford University: no partnership with the armed police hospital in Beijing-Beijing armed police hospital, Wei Zexi, Stanford University-IT information
Recommended reading : the Chinese armed police forces Beijing hospital Tingzhen posted notice: suspension of all foreign service
21-year old University computer science student Wei Zexi died of illness on April 12 this year. Two years ago, he was found belly of synovial Sarcoma, later the Internet lock "biological immune health law", and eventually selected second in Beijing, armed police corps hospital used the therapy, hospital doctor also said cooperation with Stanford.
Yesterday, United States Stanford University School of Medicine Department of media relations staff told reporters that Stanford didn't have worked with Chinese hospitals, not associated with the incident.
Yesterday, the reporter retrieved over the network found that online information displayed on the armed police Hospital Center for cancer biology, 2009, Aquatic Center and United States Stanford University, the overall introduction of complete technology for biological treatment, the formation of tumor biology Center, became the first professional biological therapy for tumor hospital. Also says in the introduction, in 2013, the armed police hospital in the original DC-CIK technology, developing upgrades for multicellular organisms, treatment, biological treatment and technology to a higher level.
More armed police hospital, reporter by searching the keyword "armed police hospital Stanford", showed that armed police hospital campaign has a similar content on the Web. Introduce a people's armed police hospital "specific anti-tumor immune therapy," in the message, saying the Beijing armed police hospital Union United States Stanford University developed a cancer immunotherapy technology, which includes DC and CIK cells, immune cells play an anti-cancer effect, saying the treatment techniques through years of clinical practice, has become one of the most mature technology of tumor immunotherapy.
But it's not the truth. Yesterday afternoon, the United States Stanford University School of Medicine Department of media relations staff told reporters that Stanford didn't have worked with Chinese hospitals, not associated with the incident.
Official website of Stanford University School of medicine, medical school research topics on CIK cells, but it is for myelodysplasia or other treatment of Myeloproliferative diseases. In terms of cancer immunotherapy, Stanford University School of medicine have carried out relevant research project, but the project information displayed in the introduction, although this tumor immunotherapy is a very promising direction conquered, but cancer immunotherapy is still at the research and testing phase, and not put to clinical treatment.
-Construction
1, synovial sarcoma is a what?
Retroperitoneal tumors of soft tissue tumor Hospital of Peking University and Associate Director of the Center introduced Qian Honggang, synovial sarcoma is a rare malignancy occur in adolescents. In less than 20 years old, crowd, synovial sarcoma of soft tissue tumors: 9%. According to United States SEER data, registered a total of 1268 patients between 1973-2005, 17% teenagers, median age is 34 years.
Synovial sarcoma of the predilection sites include limbs, trunk and retroperitoneal and other parts.
Retroperitoneal tumor of soft tissue tumor Hospital of Peking University and Director of the Center said Hao Chunyi, synovial Sarcoma, and "carcinoma" belonging to the two types of malignant tumors of different origin. One, called Sarcoma occurs in soft tissue, and the incidence of cancer, treatment and therapeutic effects are not the same. Incidence of one out of 10,000, is a rare disease, there are few clinical.
According to Xuanwu Hospital of gastrointestinal pancreatic surgery chief physician Li introduction, synovial Sarcoma, no special prior to the onset of symptoms. Long limb tumor can start, some of the swelling associated with tumors and metastasis.
2, what are the main treatment modalities?
Qian Honggang, synovial Sarcoma, main treatment modalities are surgery and chemotherapy. Expected survival time of patients with major and genotyping, and factors such as age, tumor size and extent. If it is early, the lifetime can be greater than 10, once transferred, according to the EORTC European data, lifetime is only in about 15 months.
"It is to be noted that, Wei Zexi specific illness publicly, says very little, not enough to judge and to a suitable treatment options, let alone rush to predict survival time according to the existing. "Qian Honggang said, but one thing is for sure, juvenile tragedy caused by malignant tumors is not the case.
According to Leon introduction, synovial Sarcoma, known as "the dying tumor", is a high degree of malignancy of tumor, typically, treating the tumor will try to use some surgery, assisted some chemotherapy and radiotherapy, but efficiency is lower.
Leon said that because Wei Zexi specific illness publicly, says very little, but regular will do operation auxiliary chemotherapy and radiotherapy. If these effects are not too good, might try to immunotherapy.
3, DC-CIK what kind of treatment?
Qian Honggang, DC-CIK is an immune therapy. By a large number of in vitro amplification of immune cells, transfusion patients against tumors. CIK cell was a police officer, DC cell is a hound, and help the police find the bad guys.
"This technology had existed for more than 10 years ago, but has not been widely used in the field of tumor, in medical literature retrieval on the Web can be found in the article only 105 (″ b p" "d search engine to retrieve a document of more than 26 million pieces in total), the limitation of its effects can be seen. ”
Qian Honggang said with PD1 and CART, the emergence of new technologies in recent years, tumor immunotherapy booming again, "old wine in a new bottle" some of the old technology also ushered in a "second spring". However, due to the lack of a largest randomized study, such technology is unable to assess the therapeutic effectiveness of synovial sarcoma.
According to Leon introduction, "chemotherapy and radiotherapy in the clinic of synovial sarcoma is effective, largely ineffective and DC-CIK therapy. ”
4, DC-CIK what are the main indications?
Leon introduce DC-CIK indications include lung cancer, liver cancer, stomach cancer, colon cancer, kidney cancer, acute and chronic leukemias, lymphoma, nasopharyngeal tumor, malignant melanoma, breast cancer, cervical cancer, prostate cancer, tongue cancer, thyroid cancer, and so on. But, he said, someone else did a lot of research, use of DC-CIK therapy to treat a variety of tumors, but generally found that it does not have any effect.
About DC-CIK side effects, Li said, patients may develop symptoms of fever, excitement or fatigue can occur in some patients. But there was no serious incident.
5, domestic hospitals how to?
According to app, public "intellectuals," said CIK/DC-CIK therapy had been in the United States after years of study, but its clinical trial in the United States almost all failed, the vast majority of treatments based on this method are not approved by the listing. At present, the United States has few DC-CIK therapy in clinical trials. Previous studies do not see effective curative effect, is not in clinical use, but if something changes, used in clinical research can be.
Leon introduce immune therapy for quite a number of hospitals in the country, but most of them are relatively small military hospitals or hospitals. The real city, affiliated to the Ministry of health hospital basically does not do this.
"As a rule, is still in the stage of clinical research DC-CIK therapy, hospitals to patients using this therapy, doctors generally will give the patient informed consent form, let him know that this treatment will produce the kind of results. In addition, because the treatment is currently in the research phase, in accordance with program requirements, must seek the patient whether he is willing to take part in the trial, can carry out this therapy. Therefore, it is not possible to charge. And how this treatment charges, there is no relevant provisions owned, affiliated hospitals. ”
6, immunotherapy is taken in charge?
Leon said the therapeutic techniques in medicine there in the early phase I, phase II and phase III clinical trials. Passed the test, proved to be effective can only be referenced on a large scale.
According to media reports, in accordance with the relevant provisions of management measures of medical technology clinical practice, health planning Commission prior to the ratification of this therapy organized clinical trials and ethics review. In 2014, the southern weekend reported, people in the industry said, Wei JI Wei has never organized such testing or review, cellular immunotherapy for class III medical technologies that allow clinical application.
In this regard, the scientists have wanted to come up with a reasonable solution. In 2009, the Academician Zeng Yixin combined cancer hospital affiliated to Sun Yat-sen University, Tianjin tumor hospital, Beijing 302 hospital and Chinese University of science and technology four units from four to start the research and formulation of standard of cellular immune therapy. This research project in 2013, finished and submitted to health planning, but is still below.
By May 2015, a paper order the cancellation of a third class medical technology approvals, which have not found safety and efficacy of therapies and complete walk in the grey area.
斯坦福大学：与武警北京二院无合作关系 - 北京武警二院,魏则西事件,斯坦福大学 - IT资讯
推荐阅读：《武警北京二院贴出停诊通知：暂停一切对外服务》
21岁的西安电子科技大学计算机专业学生魏则西今年4月12日因病去世。两年前，他被检查发现腹部有滑膜肉瘤，后来网上了解锁定了“生物免疫医疗法”，并最终选择在武警北京总队第二医院采用该疗法治疗，医院医生还表示与斯坦福有合作。
昨天，美国斯坦福大学医学院媒体关系部工作人员告诉记者，斯坦福大学方面并未与中国医院有过合作，与此次事件更无关联。
昨天，记者通过网络检索发现，网上关于武警二院肿瘤生物中心的信息显示，2009年，生物中心与美国斯坦福大学合作，整体引进用于生物治疗的全套技术，组建肿瘤生物中心，成为国内首家专业性肿瘤生物治疗医院。该简介中还称，2013年，武警二院在原有的DC-CIK技术上，发展升级为多细胞生物治疗，使得生物治疗的疗效和技术上了一个更高的台阶。
不止武警二院，记者通过搜索关键词“武警医院斯坦福”，结果显示，武警三院在网上的宣传中也有类似的内容。一则介绍武警三院“特异性抗肿瘤免疫疗法”的消息中，称北京武警医院联合美国斯坦福大学共同研究出一项肿瘤免疫治疗技术，即利用包括DC、CIK细胞在内的多种免疫细胞发挥抗癌作用，并称该治疗技术通过多年的临床实践，已成为我国最成熟的肿瘤免疫治疗技术之一。
但事实并非如此。昨天下午，美国斯坦福大学医学院媒体关系部工作人员告诉记者，斯坦福方面并未与中国医院有过合作，与此次事件更无关联。
斯坦福大学医学院的官方网站显示，医学院方面确有关于CIK细胞的研究课题，但该研究是针对脊髓发育不良或其他骨髓增殖性疾病的治疗方案。在肿瘤免疫治疗方面，斯坦福大学医学院也的确开展了相关的研究项目，但相关项目简介中的信息显示，尽管这种肿瘤免疫治疗是一项很有前景的攻克方向，但目前肿瘤免疫治疗仍然处在研究、试验阶段，并没有投入到临床治疗当中。
□释疑
1、滑膜肉瘤是一种什么病？
北京大学肿瘤医院软组织与腹膜后肿瘤中心副主任钱红纲介绍，滑膜肉瘤是一种较少见的恶性肿瘤，好发于青少年。在小于20岁的人群中，滑膜肉瘤占软组织肿瘤的9%。根据美国SEER的数据，1973-2005年间共登记了1268名患者，17%是青少年，中位发病年龄是34岁。
滑膜肉瘤的好发部位包括肢体、躯干、腹膜后等部位。
北京大学肿瘤医院软组织和腹膜后肿瘤中心主任郝纯毅表示，滑膜肉瘤和“癌”属于不同起源的两大类型恶性肿瘤。其中，发生于软组织的叫做肉瘤，它和癌的发病率、治疗方式和治疗效果等都不尽相同。发病率在十万分之一以下，属于罕见病，在临床上并不多见。
而据宣武医院胃肠胰腺外科副主任医师李昂介绍，滑膜肉瘤在发病前没有特别症状。但长在四肢的肿物可以作为首发的表现，另外会伴随肿瘤的部分肿痛、转移。
2、主要存在哪些治疗方式？
钱红纲表示，滑膜肉瘤主要的治疗方式有手术和化疗。预期生存时间主要和患者的基因分型、年龄、肿瘤大小及侵犯范围等因素有关。如果是早期病变，生存期可以大于10年，而一旦转移，根据欧洲EORTC的数据，生存期仅在15个月左右。
“需要指出的是，魏则西具体的病情公开的内容很少，不足以判断并给出适合的治疗选择，更无法根据现有的数据贸然预测其生存时间。”钱红钢表示，但是有一点可以确定，青少年恶性肿瘤引发的悲剧并非个案。
而据李昂介绍，滑膜肉瘤被称为“临终肿瘤”，是一种恶性程度比较高的肿瘤，通常情况下，治疗这种肿瘤会尝试用一些手术，辅助一些化疗、放疗，但是有效率比较低。
李昂表示，因为魏则西的具体病情公开的内容很少，但是常规的就是会做手术再辅助一些化疗、放疗。如果这些效果不太好，可能会尝试一些免疫疗法。
3、DC-CIK是怎样一种治疗？
钱红纲表示，DC-CIK是一种免疫治疗。通过体外大量扩增免疫细胞，回输患者体内对抗肿瘤。其中CIK细胞是警察，DC细胞是猎犬，帮助警察找到坏人。
“这一技术10余年前就已经出现，但是一直没有在肿瘤领域广泛应用，在医学专业文献检索网站上能查到的文章只有105篇(P″b““d搜索引擎总共可检索文献在2600万篇以上)，可见其效果的局限性。”
钱红纲说，近年来随着PD1及CART等新技术的出现，免疫治疗肿瘤重新火爆起来，“新瓶装旧酒”的一些老技术也迎来了“第二春”。然而由于缺乏大宗的随机对照研究，此类技术对于滑膜肉瘤的治疗效果尚无法评价。
而据李昂介绍，“化疗、放疗在临床上来说对滑膜肉瘤是有效果的，而DC-CIK疗法基本上无效。”
4、DC-CIK主要适应症是什么？
李昂介绍，DC-CIK适应症包括肺癌、肝癌、胃癌、肠癌、肾癌、急慢性白血病、淋巴瘤、恶性黑色素瘤、鼻咽瘤、乳腺癌、宫颈癌、前列腺癌、舌癌、甲状腺癌等。但他表示，以前有人做过很多研究，用DC-CIK疗法去治疗各种肿瘤，但总体上发现，它并没有任何效果。
关于DC-CIK治疗的副作用，李昂说，患者可能会出现发热的症状，有的患者会出现兴奋或者是疲劳的情况。但一般不会出现严重事件。
5、国内医院开展情况如何？
据微信公众号“知识分子”称，CIK或DC-CIK疗法此前已在美国历经多年研究，但其相关临床试验在美国基本全部宣告失败，绝大多数基于该方法的治疗技术均未得到上市批准。目前，美国已鲜有DC-CIK疗法的临床试验。前期研究没有看到有效的疗效，也就不能在临床上推广使用，但是如果有新的变化，用于临床研究还是可以。
李昂介绍，生物免疫疗法在国内医院开展的不少，但大部分都是部队医院或者相对小一点的医院。真正的市属、卫生部直属的三甲医院基本上没有做这个的。
“按照规定，DC-CIK疗法目前还处于临床研究阶段，三甲医院要对病人用这种疗法，医生一般会给病人看知情同意书，让他知道，用这种疗法会产生什么样的效果。此外，因为这种疗法目前处于研究阶段，因此按照方案要求，必须征求病人他是否愿意参加到试验中来，才可以实施这种疗法。因此，不可能给病人收费。而且这种治疗如何收费，市属、部属医院目前也还没有相关规定。”
6、免疫疗法是否接受监管？
李昂表示，治疗性的技术在医学上前期会有一期、二期、三期的临床试验。通过了试验，证明有效才可以大规模地引用。
而据有关媒体报道，按照《医疗技术临床应用管理办法》相关规定，卫计委需在批准这一疗法之前组织临床试验和伦理审查。在2014年南方周末的报道中，有业内人士曾表示，卫计委从未组织过此类试验或审查，就将细胞免疫疗法归为允许开展临床应用的第三类医疗技术。
对此，科学家们也曾想过拿出合理的解决方案。2009年，曾益新院士联合中山大学附属肿瘤医院、天津肿瘤医院、北京三零二医院和中国科技大学四家单位，从四个环节开展了细胞免疫疗法的标准研究和制定。这一研究项目在2013年结题并提交给卫计委，但至今未有下文。
而到了2015年5月，一纸命令取消了第三类医疗技术的审批工作，这项始终没有认定安全性和有效性的疗法，就此彻底游走于灰色地带。